HyungJoo Baik

HyungJoo Baik

Auto-generated profile, based on publicly available information

HyungJoo Baik

Correspondence to: HyungJoo Baik, MD, MS Division of Colorectal Surgery, Department of Surgery, Inje University Busan Paik Hospital, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan 47392, Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2018 in Anz Journal of Surgery
Verified
Journal Article
Closed access
PDF file
MAMin Sung An
Min Sung An
HBHyungJoo Baik
HyungJoo Baik
SOSe Hui Oh
Se Hui Oh
YPYo‐Han Park
Yo‐Han Park
SSSang Hyuk Seo
Sang Hyuk Seo
KBKi Beom Bae
Ki Beom Bae

1 January 2021 in Asian Journal of Surgery
Verified
Journal Article
Open access
HBHyungJoo Baik
HyungJoo Baik
KBKi Beom Bae
Ki Beom Bae
Loop ileostomy has an important role in mitigating the serious effects of anastomotic leakage in colorectal surgery. However, the morbidity and mortality associated with ileostomy reversal cannot be overlooked. We investigated the possible risk factors for complications following ileostomy reversal. All patients who underwent loop ileostomy closure between 2008 and 2017 at Inje University Busan Paik Hospital were identified. Medical records on patient characteristics, preoperative management, surgical techniques, postoperative management, chemotherapy/radiotherapy, and complications were retrospectively analyzed in a prospectively collected database. A total of 354 patients underwent loop ileostomy closure. The overall complication rate was 23.7%, with Clavien-Dindo grade I as the most common (15.8%), 5.6% in grade II, 2.2% in grade III-V, and three patients died. The two most common complications were wound infection (11.6%) and small bowel obstruction (4.8%). In univariable and multivariable analyses, closure technique or chemotherapy did not affect the outcome, but low serum albumin <3.5 g/dL (OR 7.248, CI 2.416-22.838, p < 0.001) and longer interval to ileostomy closure (OR 1.977, CI 1.167-3.350, p = 0.0113) were independent contributing factors for morbidities of ileostomy closure. Closure technique or chemotherapy did not affect the complication of ileostomy closure. However, serum albumin <3.5 g/dL and a longer interval to ileostomy closure were identified as risk factors for morbidity of ileostomy closure. These two factors should be corrected and planned before ileostomy closure.

11 July 2019 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
HKHyeongbin Kim
Hyeongbin Kim
SSSangHyuk Seo
SangHyuk Seo
KKKwangHee Kim
KwangHee Kim
YPYo-Han Park
Yo-Han Park
MAMinSung An
MinSung An
SOSangHoon Oh
SangHoon Oh
The purpose of this study was to investigate the correlation between human epidermal growth factor receptor 2 (HER2) overexpression and clinicopathologic factors and overall survival rate in patients who underwent curative gastrectomy for gastric adenocarcinoma. Among patients who underwent curative gastrectomy for gastric adenocarcinoma at Inje University Paik Hospital from January 2012 to December 2015, 782 patients underwent an immunohistochemical analysis to evaluate HER2 expression levels. Clinicopathologic records that were collected from a gastric cancer database were retrospectively reviewed to identify clinicopathologic factors and survival rates of the patients. HER2 overexpression was detected in 166 patients (21.2%). There was a statistically significant correlation between HER2 expression level and sex (p = 0.013), histologic differentiation (p < 0.001), Lauren classification (p < 0.001), and T pathologic stage (p = 0.022). There were no statistically significant relationships between HER2 expression level and overall 5-year survival rate (p = 0.775) and overall 5-year survival rate of gastric adenocarcinoma classified according to the TNM stage (stage I: p = 0.756, stage II: p = 0.571, stage III: p = 0.704). The HER2 expression level was not affected by the overall 5-year survival rate in the uni- and multivariate analyses. In this study, the HER2 overexpression rate in gastric adenocarcinoma was 21.2% and was observed in well- and moderately differentiated types according to histologic differentiation, intestinal type according to the Lauren classification, male, and low T stage. There was no correlation between HER2 expression level and overall 5-year survival rate, and HER2 expression level was not associated with independent prognostic factors.

7 July 2017 in Anz Journal of Surgery
Verified
Journal Article
Closed access
PDF file
HBHyungJoo Baik
HyungJoo Baik
SLSeok Mo Lee
Seok Mo Lee
SSSang Hyuk Seo
Sang Hyuk Seo
MAMin Sung An
Min Sung An
KKKwang Hee Kim
Kwang Hee Kim
KHKwan Hee Hong
Kwan Hee Hong

1 January 2022 in Asian Journal of Surgery
Verified
Journal Article
Open access
JPJueun Park
Jueun Park
HBHyungJoo Baik
HyungJoo Baik
SKSang Hyun Kang
Sang Hyun Kang
SSSang Hyuk Seo
Sang Hyuk Seo
KKKwang Hee Kim
Kwang Hee Kim
MAMin Sung An
Min Sung An
45% of colon cancer patients are elderly, yet they are often deviated from standard cancer management. The MOSAIC trial favored FOLFOX over FL with superior oncologic outcomes; however, which regimen is most beneficial in elderly population remains unclear. This study aimed to compare the efficacy of oxaliplatin-added chemotherapy and capecitabine monotherapy in high-risk stage II/stage III elderly colon cancer patients. Colon cancer patients ≥70 years of age who received adjuvant chemotherapy at Inje University Busan Paik Hospital between February 2009 to April 2016 were included. Patients were separated into the oxaliplatin-added group and capecitabine monotherapy group. The primary outcomes were CSS and OS. Of 74 patients, 45 received oxaliplatin-added chemotherapy and 29 received capecitabine monotherapy. There was no difference between the two groups in CSS or OS (p = 0.9670 and p = 0.6801, respectively). The N stage was significantly associated with CSS in both uni/multivariate analysis (p = 0.0565 and p = 0.0347, respectively). The oxaliplatin-added group had more stage III patients, so we performed a subgroup analysis of CSS and OS based on stage, which also showed no significant difference. Capecitabine monotherapy is an oncologically safe regimen compared to oxaliplatin-added regimens in elderly patients with high-risk stage II/stage III colon cancer.

29 March 2023 in Asian Journal of Surgery
Verified
Journal Article
Open access
JJJi Yoon Jeong
Ji Yoon Jeong
SSSang Hyuk Seo
Sang Hyuk Seo
KKKwang Hee Kim
Kwang Hee Kim
MAMin Sung An
Min Sung An
HBHyungJoo Baik
HyungJoo Baik
SOSang Hoon Oh
Sang Hoon Oh
Doxifluridine (DF), an oral 5-FU prodrug, has been used for various solid cancers due to its efficacy and low toxicity. We aim to evaluate the effect of DF as adjuvant monotherapy in advanced gastric cancer. We retrospectively reviewed the clinical data of 263 patients with advanced gastric cancer who underwent curative gastrectomy between January 2010 and December 2013 at our institute. Since previous randomized control trials have confirmed the efficacy of S-1 as adjuvant chemotherapy in advanced gastric cancer, we analyzed the oncologic effect and patient compliance of the DF group compared to the S-1 group. After propensity score matching, 48 patients were included in each group. There was no significant difference in 5-year overall survival (OS) and 5-year disease-free survival (DFS) between DF and S-1 groups (5-year OS; 77.1% vs 75.0%; p = 0.729, 5-year DFS; 76.6% vs 73.9%; p = 0.748). The completion rates of the DF and S-1 groups were 60.4% and 72.9%, respectively (p = 0.194). The mean relative dose intensity of the DF and S-1 groups were 76.2% and 84.2%, respectively (p = 0.195). After multivariate analysis, the chemotherapy regimen was not a risk factor for OS and DFS, whereas relative dose intensity and pathologic stage were independent prognostic factors. There was no significant difference in the oncologic effect and patient compliance between DF and S-1 groups. DF could be an alternative option for adjuvant chemotherapy in advanced gastric cancer. In addition, we confirmed that relative dose intensity is an important independent prognostic factor for survival.